ACTive Exoskeleton for Unilaterally-Assisted Locomotion (ACTUAL) (ACTUAL)

September 22, 2023 updated by: Fondazione Don Carlo Gnocchi Onlus

Use of a Lower Limb Exoskeleton in Locomotor Rehabilitation of Stroke Patients: Feasibility, Safety and a Pilot Clinical Study

Walking difficulties are common symptoms after stroke, significantly reducing quality of life. Walking recovery is therefore one of the main priorities of rehabilitation. Wearable powered exoskeletons have been developed to provide lower limb assistance and enable training for persons with gait impairments by using typical physiological movement patterns. Exoskeleton were originally designed for individuals without any walking capacities, such as subjects with a complete spinal cord injury. Recent systematic reviews suggested that lower limb exoskeletons could be valid tools to restore independent walking in subjects with residual motor function, such as persons post-stroke.The aim of the study was to identify the end-users needs and to develop a user-centered-based control system for the TWIN lower limb exoskeleton to provide an efficient post-stroke rehabilitation of gait. The investigators thus carried out the development and validation through evaluation sessions performed on healthy clinical experts and persons with stroke to evaluate TWIN-Acta usability, acceptability, and barriers of usage. A phase two includes a pilot study of efficacy of using the TWINActa for gait rehabilitation for persons with stroke.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The aim of the study was to identify the end-users needs and to develop a user-centered-based control system for the TWIN lower limb exoskeleton to provide post-stroke rehabilitation. The investigators thus carry out the development and validation of TWIN-Acta: a novel control suite for TWIN, specifically designed for gait rehabilitation of persons post stroke through use of typical physiological movement patterns.

The study will be carried out in two phases. In the first user-centered developmental phase data on usability, acceptability, and limitations to system usage will be collected from clinical experts and persons with stroke through questionnaires and semi-structured interviews.This developmental phase will follow a user-centered approach: it will be based on focus group sessions with clinical and biomechanical experts to define the design specifications for the new control modality of the exoskeleton; consequently evaluation sessions consisting of physical testing of the TWIN-Acta will be carried out by healthy clinical experts and persons with stroke to evaluate TWIN-Acta usability, acceptability, and barriers of usage.

In the second phase of the study a pilot study including 20 sessions of gait rehabilitation of persons at least three month post stroke will be carried out in clinic with the TWIN exoskeleton including the TWIN-Acta control suite.

Outcomes will be verified at baseline and following the intervention through feasibility measures, patient reported outcomes, clinical measures of gait ability and through EMG and 3D gait analysis. The quantitative values will be compared to data of healthy controls walking in the exoskeleton in one session but not receiving any intervention.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy subjects

    • Age 30-75 anni;
    • 50 kg ≤ weight ≤90 kg
    • 150 cm ≤ height ≤ 192 cm
    • Thigh length: 355 ÷ 475 mm;
    • Length of tibia: 405 ÷ 485 mm;
    • Width pelvis: 690 ÷ 990 mm;
    • Shoe number: 36 ÷ 45
  • Subjects with stroke

    • Age 30-75 anni;
    • 50 kg ≤ Weight ≤90 kg
    • 150 cm ≤ Height ≤ 192 cm
    • Thigh length: 355 ÷ 475 mm;
    • Length of tibia: 405 ÷ 485 mm;
    • Pelvic width: 690 ÷ 990 mm;
    • Shoe number: 36 ÷ 45;
    • Stroke diagnosis at least 3 months and within 24 months;
    • First unilateral haemorrhagic or ischemic stroke classified as complete or partial infarction of the anterior circulation and infarction of the lacunar circulation (Oxford Stroke Classification: TACS -Total Anterior Circulation Stroke, PACS - Partial Anterior Circulation Stroke, LACS -Lacunar Stroke). These criteria may include hemiplegia, hemianopia, motor and/or sensory deficits, and disturbance/impairment of superior cortical and subcortical function;
    • FAC (Functional Ambulation Category) 1, 2 and 3 (subjects with ambulation dependent on supervisor or continuous or intermittent physical assistance);
    • At least MRC (Medical Research Council) of the triceps surae equal to 1 or greater (required to produce the biofeedback tone or for exoskeleton control).

Exclusion Criteria:

  • Healthy subjects

    • Prosthetic implants
    • Musculoskeletal, neurological, cardiovascular and pulmonary disorders that may impair gait;
    • State of pregnancy or breastfeeding.

Exclusion criteria

  • Subjects with stroke

    • Mini Mental State Examination < 23/30;
    • Clinical records of visuospatial and ideomotor apraxia, behavioral disorders (e.g. depression, aggression), neglect, major visual impairment and severe osteoporosis;
    • Non stabilized fractures;
    • Cranial injury;
    • Other diseases attributable to cardio-respiratory problemsi;
    • State of pregnancy or breastfeeding;
    • Previous or concurrent neoplasic malignancy;
    • Chronic inflammatory diseases with joint involvement of the lower limbs;
    • Serious spasticity (Ashworth>3);
    • Pelvic fractures and unstable column;
    • Significant limitations of passive ROM of hips and knees;
    • Problems with skin integrity at the interface surfaces with the device or that would prevent sitting.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exoskeleton Stroke group
This group will receive gait rehabilitation with the exoskeleton for 20 sessions in clinic.
The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
Other Names:
  • TWIN-Acta exoskeleton
No Intervention: Healthy control group
The quantitative data, including EMG and 3D kinematics, from 10 healthy controls walking with the exoskeleton will serve as comparative data for the experimental group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in meters walked during the Two minute walking test
Time Frame: Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
The subjects were instructed to walk at their usual speed for 2 minutes while the distance they covered in 2 minutes was recorded in meters.
Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in score on the Ashworth scale
Time Frame: Baseline (T0) and after 4 weeks (T1)
The Ashworth scale is a muscle tone assessment scale used to assess the resistance experienced during passive range of motion
Baseline (T0) and after 4 weeks (T1)
Change in score on the Muscle Manual Test (MMT)
Time Frame: Baseline (T0) and after 4 weeks (T1)
MMT is a standardized set of assessments that measure muscle strength and function
Baseline (T0) and after 4 weeks (T1)
Change in time (sec) taken to Timed up and Go
Time Frame: Baseline (T0) and after 4 weeks (T1)
The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance.
Baseline (T0) and after 4 weeks (T1)
Change time (sec) taken to complete the Five time sit to stand (5xSTS)
Time Frame: Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
The 5xSTS measures the amount of time it takes for a patient to sit and stand five times in succession with arms folded across their chest.
Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
Change in score on the Stroke impact Scale (SIS) questionnaire
Time Frame: Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
The Stroke Impact Scale (SIS) is a self-report questionnaire that evaluates disability and health-related quality of life after stroke
Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
Change in time (sec) taken to complete the 10 meter walking test (10mwt)
Time Frame: Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
The 10 meters walking test (10MWT) is a test in which the participant is timed while walking 10m at their comfortable speed.
Baseline (T0) and after 4 weeks (T1) and after 3 months (T2)
Changes in movement parameters extracted from the kinematics of the body.
Time Frame: Baseline (T0) and after 4 weeks (T1)

Kinematics of the lower limb will be recorded using a 9 camera optoelectronic system during 3D motor acts.

The system will measure the 3D coordinates of spherical markers attached to body landmarks to compute hip, knee and ankle angles.

Data processing will provide measures of deviations from physiological movement.

Baseline (T0) and after 4 weeks (T1)
Correlation between brain activity parameters and motor activity parameters
Time Frame: Baseline (T0) and after 4 weeks (T1)

Brain activity data acquired with electroencephalogram (EEG) correlated with data from electromyographic systems.

Data processing will provide measures of deviations from physiological movement.

Baseline (T0) and after 4 weeks (T1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 12, 2021

Primary Completion (Estimated)

March 31, 2024

Study Completion (Estimated)

March 31, 2024

Study Registration Dates

First Submitted

July 4, 2023

First Submitted That Met QC Criteria

September 22, 2023

First Posted (Actual)

September 29, 2023

Study Record Updates

Last Update Posted (Actual)

September 29, 2023

Last Update Submitted That Met QC Criteria

September 22, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke Sequelae

Clinical Trials on Exoskeleton stroke group

3
Subscribe